Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Other (2017 - 2025)

Crinetics Pharmaceuticals has reported Receivables - Other over the past 9 years, most recently at $7.8 million for Q4 2025.

  • Quarterly results put Receivables - Other at $7.8 million for Q4 2025, down 6.64% from a year ago — trailing twelve months through Dec 2025 was $7.8 million (down 6.64% YoY), and the annual figure for FY2025 was $7.8 million, down 6.64%.
  • Receivables - Other for Q4 2025 was $7.8 million at Crinetics Pharmaceuticals, up from $6.3 million in the prior quarter.
  • Over the last five years, Receivables - Other for CRNX hit a ceiling of $8.4 million in Q2 2025 and a floor of $85000.0 in Q1 2021.
  • Median Receivables - Other over the past 5 years was $1.3 million (2022), compared with a mean of $2.8 million.
  • Biggest five-year swings in Receivables - Other: crashed 93.35% in 2023 and later surged 9133.33% in 2024.
  • Crinetics Pharmaceuticals' Receivables - Other stood at $553000.0 in 2021, then surged by 144.67% to $1.4 million in 2022, then crashed by 93.35% to $90000.0 in 2023, then surged by 9133.33% to $8.3 million in 2024, then decreased by 6.64% to $7.8 million in 2025.
  • The last three reported values for Receivables - Other were $7.8 million (Q4 2025), $6.3 million (Q3 2025), and $8.4 million (Q2 2025) per Business Quant data.